Literature DB >> 10075966

The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre.

C Datz1, M Cramp, T Haas, O Dietze, H Nitschko, G Froesner, N Muss, F Sandhofer, W Vogel.   

Abstract

BACKGROUND: The natural history of hepatitis C virus (HCV) infection is variable and factors determining the course of the illness are unclear. AIMS: To determine the natural course of HCV infection in a well characterised group of patients 18 years after an epidemic outbreak of non-A, non-B hepatitis at a plasmapheresis centre.
METHODS: Between 1994 and 1996, 20 of 30 affected individuals were studied. HCV infection was confirmed using second and third generation ELISA test kits. HCV RNA was detected by a polymerase chain reaction (PCR) method and HCV genotyping was performed by analysing amplicons from the conserved 5'-non-translated region generated by nested PCR. Thirty two liver biopsies were carried out in 14 patients.
RESULTS: HCV antibodies were detected in all subjects. Eighteen patients had abnormal liver enzymes and 17 were HCV RNA positive, all of whom were infected with genotype 1a. Ninety per cent of this cohort showed evidence of chronic HCV infection with 50% having progressive liver disease and 20% cirrhosis 18 years after acute onset of non-A, non-B hepatitis. Considerable variation in disease outcome occurred between individuals and no correlation with clinical features of the acute illness was found.
CONCLUSIONS: Variability in the consequences of HCV infection in cases infected with the same virus suggests that host factors are important in determining disease outcome. The factors which determine differences in the natural history of the disease still remain to be elucidated.

Entities:  

Mesh:

Year:  1999        PMID: 10075966      PMCID: PMC1727458          DOI: 10.1136/gut.44.4.563

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Primary HIV infection: host responses and intervention strategies.

Authors:  B Tindall; D A Cooper
Journal:  AIDS       Date:  1991-01       Impact factor: 4.177

3.  Long-term persistence of hepatitis C virus antibodies in a single source outbreak.

Authors:  S Dittmann; M Roggendorf; J Dürkop; M Wiese; B Lorbeer; F Deinhardt
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

4.  Epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis center. I: Epidemiological observations.

Authors:  N Muss; G G Frösner; F Sandhofer
Journal:  Infection       Date:  1985 Mar-Apr       Impact factor: 3.553

5.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

6.  Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis.

Authors:  A M Di Bisceglie; Z D Goodman; K G Ishak; J H Hoofnagle; J J Melpolder; H J Alter
Journal:  Hepatology       Date:  1991-12       Impact factor: 17.425

7.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

8.  Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group.

Authors:  L B Seeff; Z Buskell-Bales; E C Wright; S J Durako; H J Alter; F L Iber; F B Hollinger; G Gitnick; R G Knodell; R P Perrillo
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis.

Authors:  F Tremolada; C Casarin; A Alberti; C Drago; A Tagger; M L Ribero; G Realdi
Journal:  J Hepatol       Date:  1992-11       Impact factor: 25.083

10.  Natural course of chronic hepatitis C.

Authors:  M Takahashi; G Yamada; R Miyamoto; T Doi; H Endo; T Tsuji
Journal:  Am J Gastroenterol       Date:  1993-02       Impact factor: 10.864

View more
  10 in total

Review 1.  Acute hepatitis C virus infection: a chronic problem.

Authors:  Jason T Blackard; M Tarek Shata; Norah J Shire; Kenneth E Sherman
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

2.  Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients.

Authors:  M G Rumi; F De Filippi; C La Vecchia; M F Donato; S Gallus; E Del Ninno; M Colombo
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

3.  Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex.

Authors:  K S Brown; M J Keogh; N Tagiuri; M J Grainge; J S Presanis; S D Ryder; W L Irving; J K Ball; R B Sim; T P Hickling
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 4.  Hepatitis C-Z: recent advances.

Authors:  D Kelly; S Skidmore
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

5.  Prospective study in 142 cases of hepatitis C virus infection.

Authors:  Wen-Mei Fan; Wan-Fu Zhu; Li-Min Yin; Lai Wei; Xiao-Yuan Xu; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

6.  Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy.

Authors:  M L Alves Pedroso; A B W Boldt; L Pereira-Ferrari; R Steffensen; E Strauss; J C Jensenius; S O Ioshii; I Messias-Reason
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

7.  Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C.

Authors:  J P Colagreco; D E Bailey; J J Fitzpatrick; C M Musil; N H Afdhal; M Lai
Journal:  J Viral Hepat       Date:  2013-11-07       Impact factor: 3.728

8.  Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data.

Authors:  Andrea Marcellusi; Raffaella Viti; Loreta A Kondili; Stefano Rosato; Stefano Vella; Francesco Saverio Mennini
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

9.  Causes of Persistently Elevated Alanine Aminotransferase Levels in Patients who Presented to Two Referral Hospitals in Mashhad, Iran during 2011.

Authors:  Ahmad Khorashad; Hassan Vossoughinia; Hassan Saadatnia; Abbas Esmaelzadeh; Mitra Ahadi; Mohammad Reza Farzanehfar; Seyed Mossareza Hosseini; Monavvar Afzalaghaii; Elham Amirmajdi; Linda Barari; Farzad Saadatnia
Journal:  Middle East J Dig Dis       Date:  2014-01

10.  Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update.

Authors:  Aysegul Erman; Murray D Krahn; Tawnya Hansen; Josephine Wong; Joanna M Bielecki; Jordan J Feld; William W L Wong; Paul Grootendorst; Hla-Hla Thein
Journal:  BMJ Open       Date:  2019-11-11       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.